Beneficial Acute Hemodynamic Effects of Sacubitril-Valsartan in Patients with Low-Cardiac Output Including Significant Improvement in PAPi
PIONEER-HF established the safety of the angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril-valsartan (S/V), in patients hospitalized with acute decompensated heart failure after achieving hemodynamic stability. We have previously shown that transitioning patients in cardiogenic shock directly from intravenous (IV) vasoactive (i.e. vasodilators or inotropes) drugs to S/V can be done safely with tolerance to one-month follow-up. Here we further characterize the hemodynamic impact of S/V after patients have been optimized on vasoactive therapy.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: T. Martyn, K.D. Faulkenberg, C.L. Albert, Z.J. Il'Giovine, R.A. Montgomery, V.K. Randhawa, D.M. Yaranov, V. Menon, J.D. Estep, W. Tang, R.C. Starling Tags: (111) Source Type: research
More News: Cardiogenic Shock | Cardiology | Diovan | Heart | Heart Failure | Heart Transplant | Lung Transplant | Men | Transplant Surgery | Transplants